首页> 外文OA文献 >Katanosin B and Plusbacin A3, Inhibitors of Peptidoglycan Synthesis in Methicillin-Resistant Staphylococcus aureus
【2h】

Katanosin B and Plusbacin A3, Inhibitors of Peptidoglycan Synthesis in Methicillin-Resistant Staphylococcus aureus

机译:Katanosin B和Plusbacin A3,耐甲氧西林金黄色葡萄球菌肽聚糖合成的抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Both katanosin B and plusbacin A3 are naturally occurring cyclic depsipeptide antibiotics containing a lactone linkage. They showed strong antibacterial activity against methicillin-resistant Staphylococcus aureus and VanA-type vancomycin-resistant enterococci, with MICs ranging from 0.39 to 3.13 μg/ml, as well as against other gram-positive bacteria. They inhibited the incorporation of N-acetylglucosamine, a precursor of cell wall synthesis, into peptidoglycan of S. aureus whole cells at concentrations close to their MICs. In vitro studies with a wall-membrane particulate fraction of S. aureus showed that katanosin B and plusbacin A3 inhibited the formation of lipid intermediates, with 50% inhibitory concentrations (IC50s) of 2.2 and 2.3 μg/ml, respectively, and inhibited the formation of nascent peptidoglycan, with IC50s of 0.8 and 0.4 μg/ml, respectively. Vancomycin, a well-known inhibitor of transglycosylation, did not inhibit the formation of lipid intermediates but did inhibit the formation of nascent peptidoglycan, with an IC50 of 4.1 μg/ml. Acetyl-Lys-d-Ala-d-Ala, an analog of the terminus of the lipid intermediates, effectively suppressed the inhibition of transglycosylation by vancomycin, but did not suppress those by katanosin B and plusbacin A3. These results indicate that the antibacterial activity of katanosin B and plusbacin A3 is due to blocking of transglycosylation and its foregoing steps of cell wall peptidoglycan synthesis via a mechanism differing from that of vancomycin.
机译:katanosin B和plusbacin A3均为天然存在的具有内酯键的环状双缩肽抗生素。它们对耐甲氧西林的金黄色葡萄球菌和耐VanA型耐万古霉素的肠球菌显示出强大的抗菌活性,MIC范围为0.39至3.13μg/ ml,并且对其他革兰氏阳性细菌也有良好的抗菌作用。他们抑制了N-乙酰氨基葡萄糖(细胞壁合成的前体)以接近其MIC的浓度掺入金黄色葡萄球菌全细胞的肽聚糖中。对金黄色葡萄球菌壁膜微粒级分的体外研究表明,激肽释放酶B和加菌素A3抑制脂质中间体的形成,其50%抑制浓度(IC50s)分别为2.2和2.3μg/ ml,并抑制了脂质中间体的形成。新生肽聚糖的IC50分别为0.8和0.4μg/ ml。万古霉素是一种著名的转糖基化抑制剂,它不抑制脂质中间体的形成,但可以抑制新生肽聚糖的形成,IC50为4.1μg/ ml。乙酰基-赖氨酸-d-丙氨酸-d-丙氨酸是脂质中间体末端的类似物,可有效抑制万古霉素对转糖基化的抑制作用,但不能抑制卡他诺菌素B和加菌素A3的抑制作用。这些结果表明,katanosin B和plusbacin A3的抗菌活性是由于转糖基作用的阻断以及其通过不同于万古霉素的机制的细胞壁肽聚糖合成的前述步骤所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号